# BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

> **NCT05977036** · NA · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 65 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Unresectable Breast Cancer

## Interventions

- **DEVICE:** DiviTum® TKa assay
- **DRUG:** CDK4/6 + Endocrine therapy

## Key facts

- **NCT ID:** NCT05977036
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-25
- **Primary completion:** 2034-09-30
- **Final completion:** 2034-09-30
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05977036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05977036, "BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05977036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*